MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 26.03.2026
NeuroBo Pharmaceuticals Gesamtverbindlichkeiten 2011-2026 | NRBO
Gesamtverbindlichkeiten Jährlich NeuroBo Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.79 M | 8.33 M | 6.1 M | 11.8 M | 2.2 M | 3.76 M | 2.18 M | 11.9 M | 15.1 M | 4.12 M | 16.9 M | 879 K | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 16.9 M | 879 K | 7.42 M |
Gesamtverbindlichkeiten Vierteljährlich NeuroBo Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.43 M | 8.84 M | 7.75 M | 8.33 M | 9.19 M | 9.81 M | - | 6.1 M | 4.88 M | 3.98 M | 11 M | 11.8 M | 1.62 M | 1.25 M | 1.53 M | 2.2 M | 1.95 M | 1.24 M | 1.01 M | 3.76 M | 3.76 M | 3.76 M | 3.76 M | 2.18 M | 2.18 M | 2.18 M | 2.18 M | 360 K | 11.9 M | 11.9 M | 11.9 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 4.12 M | 4.12 M | 4.12 M | 4.12 M | 8.92 M | 8.92 M | 8.92 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 15.1 M | 360 K | 6.45 M |
Gesamtverbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtverbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
455 M | $ 22.56 | 2.13 % | $ 3.74 B | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
Akebia Therapeutics
AKBA
|
344 M | $ 1.43 | 3.62 % | $ 368 M | USA |
 |
argenx SE
ARGX
|
1.36 B | $ 785.07 | 2.57 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B |  France |
 |
Alnylam Pharmaceuticals
ALNY
|
4.18 B | $ 327.25 | 2.42 % | $ 42.9 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | France |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.66 | 3.5 % | $ 16.7 M | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.9 | 3.7 % | $ 9.38 B |  Australia |
 |
CymaBay Therapeutics
CBAY
|
142 M | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
840 M | $ 20.4 | -0.87 % | $ 954 M | USA |
 |
Aquestive Therapeutics
AQST
|
194 M | $ 4.18 | 1.21 % | $ 447 M | USA |
 |
Avid Bioservices
CDMO
|
276 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
51.5 M | - | - | $ 1.41 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
243 M | $ 24.61 | 5.76 % | $ 3.13 B | USA |
 |
Cabaletta Bio
CABA
|
53 M | $ 3.09 | 0.65 % | $ 310 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
53.1 M | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
411 M | $ 1.49 | 9.56 % | $ 397 M | Britain |
 |
CTI BioPharma Corp.
CTIC
|
144 M | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.34 M | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
123 M | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
389 M | - | - | $ 2.02 B | USA |
|
Forte Biosciences
FBRX
|
21.8 M | $ 26.27 | 0.38 % | $ 340 M | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
19.6 M | $ 3.88 | 2.11 % | $ 261 B | Britain |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |